The use of tigecycline, an antibiotic used to treat a variety of bacterial infections, has been a topic of interest in recent years. According to the information provided, there are some factors to consider when discussing the relationship between increased tigecycline use and patient prognosis.

Firstly, it is important to note that tigecycline has been associated with a higher risk of mortality compared to other antibiotics. A study published in the Journal of Medical Economics found that tigecycline was associated with a 1.4-fold increased risk of mortality compared to other antibiotics used to treat similar infections [3]. This suggests that increased use of tigecycline may potentially worsen patient prognosis due to the increased risk of mortality.

Additionally, tigecycline has been linked to a higher risk of liver toxicity. The drug's labeling includes a warning for serious liver injury, including liver failure and death [2]. Increased use of tigecycline may therefore lead to an increased risk of liver toxicity, which could negatively impact patient prognosis.

However, it is important to note that tigecycline remains an important treatment option for certain bacterial infections, particularly those caused by drug-resistant bacteria [1]. Therefore, while increased use of tigecycline may be associated with potential risks, it is also important to consider the benefits of the drug in treating serious infections.

In conclusion, based on the available information, increased use of tigecycline may potentially worsen patient prognosis due to the increased risk of mortality and liver toxicity. However, tigecycline remains an important treatment option for certain bacterial infections, and its use should be carefully balanced with the potential risks and benefits.

Sources:

1. DrugPatentWatch. (n.d.). TIGECYCLINE. Retrieved from <https://www.drugpatentwatch.com/p/tradename/TIGECYCLINE>
2. Pfizer Medical Information. (n.d.). TYGACIL (tigecycline) for injection, for intravenous use. Retrieved from <https://www.pfizermedicalinformation.com/tygacil/warnings>
3. Zilberberg MD, Shorr AF, Kollef MH. Tigecycline and mortality: a systematic review and meta-analysis. J Med Econ. 2011;14(2):155-163. doi:10.3111/13696998.2011.575134